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Sir,
The BOADICEA model of genetic susceptibility to breast and
ovarian cancer was developed using complex segregation analysis
of breast and ovarian cancer (Antoniou et al, 2002, 2004). We agree
with van Asperen et al that as it stands, the model is not easy to use
in clinical practice. However, the model is currently being
implemented in web-based software that will provide a user-
friendly tool for clinical geneticists and oncologists. We disagree
however with the premise that the model is particularly hard to
understand. The BOADICEA model incorporates the effects of
BRCA1, BRCA2 and other genes. Although it has more risk
parameters than some other models, it is conceptually quite
similar to the Claus et al (1991) or BRCAPRO models (Parmigiani
et al, 1998), or the model proposed by Jonker et al (2003). The
major difference is the incorporation of a polygenic component to
explain familial aggregation of breast cancer not attributable to
BRCA1 and BRCA2.
van Asperen et al question the low breast cancer risk (13% by
age 70) estimated for the index woman in Figure 3 of our paper.
We agree that this estimate is probably anomalously low, due to
imprecision in the BRCA1 and BRCA2 penetrance estimates we
used. The average risk of breast cancer in BRCA1 mutation carriers
in the first version of the BOADICEA model was estimated to be
35% by age 70 (Antoniou et al, 2002), which is much lower than the
estimates used in the Jonker et al (2003). However, the BRCA1 and
BRCA2 incidence rates used in the first version of BOADICEA were
based on relatively small numbers of BRCA1 and BRCA2 mutation
positive families (62 in total) and may therefore be imprecise.
To improve the risk prediction, we have recently refitted the
BOADICEA model using additional data from two UK population-
based studies of breast cancer (Peto et al, 1999; Lalloo et al, 2003)
and data from the meta-analysis of the families of BRCA1/2
carriers identified through population-based studies of breast and
ovarian cancer (Antoniou et al, 2003). The updated data set
includes more than 500 BRCA1 and BRCA2 mutation positive
families, and therefore the incidence rates are estimated more
reliably (manuscript in preparation). In the updated version, the
average risk of breast cancer in BRCA1 mutation carriers by age 70
varies between 50 and 59% depending on the year of birth.
Applying the latest version of the model to the family in Figure 2 of
Antoniou et al (2004), the 40-year-old woman is predicted to carry
a BRCA1 mutation with probability 41% and a BRCA2 mutation
with a probability 1% (very similar to the previous estimates).
However, her predicted risk of developing breast cancer by age 70
is now higher, 28%, perhaps closer to the expectations of van
Asperen and co-workers.
van Asperen et al question the fact that the presence of ovarian
cancer in the family does not affect the breast risk. It is a feature
common to BOADICEA and all the other risk prediction models,
however, that the risks of breast and ovarian cancer in a family are
assumed to be independent given the BRCA1 and BRCA2
genotypes. Thus, the presence of ovarian cancer in the family
only affects the breast cancer risk in so far as it affects the BRCA1
and BRCA2 carrier probabilities.
We agree that the regression model of van Asperen et al (2004)
can be more easily used in clinical practice. However, this model
cannot deal with the complex family histories seen in genetic
*Correspondence: Professor DF Easton;
E-mail: doug.easton@srl.cam.ac.uk
Published online 22 March 2005
Letters to the Editor
1337
British Journal of Cancer (2005) 92(7), 1336–1338 & 2005 Cancer Research UKclinics. Moreover, the model was derived by linear regression of
the independent variables on the predictions given the Jonker et al
(2003) model. Therefore, the validity of the regression formula
critically depends on an as yet (to our knowledge) unvalidated
model. In any event, evaluation of the accuracy of any model in
predicting the correct carrier and cancer risks should be based on
validation studies in independent series and not on the basis of
individual families.
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